WallStSmart

Boston Scientific Corp (BSX)vsenVVeno Medical Corp (NVNO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

BSX leads profitability with a 17.3% profit margin vs 0.0%. BSX earns a higher WallStSmart Score of 76/100 (B+).

BSX

Strong Buy

76

out of 100

Grade: B+

Growth: 8.0Profit: 7.0Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.78

NVNO

Avoid

27

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -2.51
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXSignificantly Overvalued (-19.8%)

Margin of Safety

-19.8%

Fair Value

$37.36

Current Price

$44.77

$7.41 premium

UndervaluedFair: $37.36Overvalued

Intrinsic value data unavailable for NVNO.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX5 strengths · Avg: 8.6/10
EPS GrowthGrowth
100.0%10/10

Earnings expanding 100.0% YoY

Market CapQuality
$66.87B9/10

Large-cap with strong market position

PEG RatioValuation
0.548/10

Growing faster than its price suggests

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.6%8/10

Strong operational efficiency at 20.6%

NVNO2 strengths · Avg: 10.0/10
Price/BookValuation
0.3x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

BSX1 concerns · Avg: 4.0/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

NVNO4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$7.42M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 17.3% and operating margin at 20.6%. Revenue growth of 11.6% demonstrates continued momentum.

Bull Case : NVNO

The strongest argument for NVNO centers on Price/Book, Debt/Equity.

Bear Case : BSX

The primary concerns for BSX are Altman Z-Score.

Bear Case : NVNO

The primary concerns for NVNO are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

BSX profiles as a mature stock while NVNO is a value play — different risk/reward profiles.

NVNO carries more volatility with a beta of 1.09 — expect wider price swings.

BSX is growing revenue faster at 11.6% — sustainability is the question.

BSX generates stronger free cash flow (171M), providing more financial flexibility.

Bottom Line

BSX scores higher overall (76/100 vs 27/100), backed by strong 17.3% margins and 11.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

enVVeno Medical Corp

HEALTHCARE · MEDICAL DEVICES · USA

enVVeno Medical Corp (NVNO) is a pioneering medical device firm focused on revolutionizing vascular access solutions for dialysis patients with its proprietary biocompatible technology. By aiming to fulfill essential unmet needs within the dialysis sector, the company enhances the safety and effectiveness of vascular procedures, positioning itself to capture significant growth in the vascular interventions market. With a strong commitment to advanced engineering and compliance with regulatory standards, enVVeno is well-aligned with the dynamic landscape of healthcare, underscoring its mission to elevate patient outcomes in this critical area.

Want to dig deeper into these stocks?